Dendrite Acquires Assets of OPUS Health, a Leading Supplier of Patient Persistence Technology
05 9월 2006 - 10:31PM
Business Wire
Dendrite International, Inc. (NASDAQ:DRTE) a leading provider of
sales and marketing solutions to the pharmaceutical industry, today
announced the acquisition of substantially all the assets of OPUS
Health LLC, a leading provider of direct-to-patient persistence
technologies. The acquisition cements an existing agreement between
the two companies that enables Dendrite to provide the industry's
most complete end-to-end, multi-channel persistence solution, which
links pharmaceutical companies, prescribers, pharmacies and
patients. OPUS Health will operate as a division of Dendrite within
the Marketing Solutions business. Patient persistence is a
far-reaching problem for all key healthcare constituents: patient,
provider, payor, pharmaceutical/biotech manufacturer, pharmacy and
government. Simply put, when patients don't take their medications
properly, it lessens the health benefit for the patient and thereby
increases costs for the entire system. Dendrite believes patient
persistence programs will be a large market and ultimately evolve
into an even larger disease management market. OPUS Health is an
early-stage company and pioneer in direct-to-patient technologies.
Dendrite adds its breadth of marketing services around OPUS Health
technology to deliver complete patient persistence programs and
analysis. As partners, Dendrite and OPUS Health have already
provided such programs for more than 40 pharmaceutical brands. This
strategic acquisition allows Dendrite to reinforce its early lead
in the first generation of electronic direct-to-patient programs
and position it for leadership in future generations of these
technologies. "The acquisition of OPUS Health is consistent with
our strategy to be a leader in direct-to-patient persistence
solutions," said Carl Cohen, president of Dendrite Marketing
Solutions. "Patients respond to the solution because of its ease of
use, instant point-of-sale nature, and availability at their local
pharmacies. Our customers and other healthcare constituents value
the end-to-end nature of our programs, which improve patient health
and help lower overall costs." "Dendrite has always been an
industry visionary and we are glad to be joining the Dendrite
family," said Harvey Brofman, vice president and general manager of
the OPUS Health group at Dendrite. "With the acquisition of OPUS
Health into its Marketing Solutions group, Dendrite has a more
powerful, streamlined solution in the area of patient persistence.
We also believe that being part of Dendrite can enhance our product
offering to partners and strengthen our relationships with them."
About Dendrite Founded in 1986, Dendrite International (NASDAQ:
DRTE) enables sales, marketing, clinical and compliance solutions
for the global pharmaceutical industry. The Company's clients are
located in more than 50 countries and include the world's top 20
pharmaceutical companies. For more information, please visit
www.dendrite.com. For more information on OPUS Health, please visit
www.opushealth.com. About OPUS Health OPUS Health assets were sold
to Dendrite by OCI Ventures, LLC a privately held company whose
other Division, OPUS-ISM, LLC is a leading provider of pharmacy
management systems and pharmacy workflow technology to retail
pharmacies, HMOs and PBMs. Note: Dendrite is a registered trademark
of Dendrite International, Inc. This document may contain
forward-looking statements that may be identified by such
forward-looking terminology as "expect," "believe," "anticipate,"
"will," "intend," "plan," "target," "outlook," "guidance," and
similar statements or variations. Such forward-looking statements
are based on our current expectations, estimates, assumptions and
projections and involve significant risks and uncertainties,
including risks which may result from our dependence on the
pharmaceutical industry; our fixed expenses in relation to
fluctuating revenues and variations in customers' budget cycles;
dependence on certain major customers, including the risk
associated with one substantial customer currently assessing its
U.S. sales force effectiveness services needs; our ability to
successfully implement our Operational Effectiveness program and to
achieve the cost savings in the amounts and time periods expected
or budgeted; changes in demand for our products and services
attributable to any weakness experienced in the economy or mergers,
acquisitions and consolidations in the pharmaceutical industry;
risks associated with foreign currency fluctuations and our ability
to adapt and respond successfully to other unique risks involved in
our non-U.S. operations; integrating the entities we acquire; and
our ability to effectively manage our growth. Other important
factors that should be reviewed and carefully considered are
included in the company's 10-K, 10-Qs, and other reports filed with
the SEC. Actual results may differ materially. The company assumes
no obligation for updating any such forward-looking statements to
reflect actual results, changes in assumptions or other changes
affecting such forward-looking statements and the information
provided in this press release should not be construed as updating,
modifying or confirming the company's most recent financial outlook
or guidance.
Dendrite (NASDAQ:DRTE)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Dendrite (NASDAQ:DRTE)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024